Follow the Maze Therapeutics, Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €1.5bn. The latest transaction was filed on 31 August 2026 (Levée d'options). Among the most active insiders: Bernstein Harold. All data is accessible without an account.
63
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€4m
28 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Maze Therapeutics, Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$62.55.
48Σ signal
Buys n/a€4m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 28,286 of 29,053 companies
11.6
score / 100
Value
18
Quality
5
FCF yld-7.4%
Earn yld-8.6%
EV/EBITDA·
ROE-37%
Gross mgn·
Net mgn-91%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
13,253 shares@ US$25.574663.2% of flowCommon StockSEC:0002050172-26-000023:1
25 of 63 declarations
About Maze Therapeutics, Inc.
Maze Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for genetic diseases. It employs innovative approaches to identify and develop targeted treatments.